Lurasidone in the treatment of schizophrenia: a critical evaluation

Bibliography

• Torres-Gonzalez F, Ibanez-Casa I, Saldivia S, et al. Unmet needs in the management of schizophrenia. Neuropsychiatr Dis Treat 2014;10:97-110
   PubMed Web of Science ®Google Scholar
• Tandon R, Gaebel W, Barch D, et al. Schizophrenia in the DSM-5. Schizophr Res 2013;150:3-10
   PubMed Web of Science ®Google Scholar
• Citrome L. Unmet needs in the treatment of schizophrenia: new targets to help different symptom domains. J Clin Psychiatry 2014;75(Suppl 1):21-6
   PubMed Web of Science ®Google Scholar
• Kane JM, Correll CU. Past and present progress in the pharmacological treatment of schizophrenia. J Clin Psychiatry 2010;71:1115-24
   PubMed Web of Science ®Google Scholar
• Tandon R. Antipsychotics in the treatment of schizophrenia: An overview. J Clin Psychiatry 2011;72(Suppl 1):4-8
   PubMed Web of Science ®Google Scholar
• Tandon R, Nasrallah HA, Keshavan MS. Schizophrenia, “Just the facts” 5. Treatment and Prevention. Schizophr Res 2010;122(1-3):1-23
   PubMed Web of Science ®Google Scholar
• Meyer JM, Loebel AD, Schweizer E. Lurasidone: a new drug in development for schizophrenia. Expert Opin Investig Drugs 2009;18(11):1715-26
   PubMed Web of Science ®Google Scholar
• Preskorn S, Ereshefsky L, Chiu Y-Y, et al. Effect of food on the pharmacokinetics of lurasidone: results of two randomized, open-label, cross-over studies. Hum Psychopharmacol 2013;28(5):495-505
   PubMed Web of Science ®Google Scholar
• Chiu Y-Y, Erefshefsky L, Preskorn SH, et al. Lurasidone drug-drug interaction studies: a comprehensive review. Drug Metabol Drug Interact 2014;29(3):191-202
   PubMedGoogle Scholar
• Nakamura M, Ogasa M, Guarino J, et al. Lurasidone in the treatment of acute schizophrenia: A double-blind, placebo-controlled trial. J Clin Psychiatry 2009;70(6):829-36
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Cucchiaro J, Silva R, et al. Lurasidone in the treatment of schizophrenia: A randomized, double-blind, placebo- and olanzapine- controlled study. Am J Psychiatry 2011;168(9):957-67
   PubMed Web of Science ®Google Scholar
• Nasrallah HA, Silva R, Phillips D, et al. Lurasidone for the treatment of acutely psychotic patients with schizophrenia: A 6-week, randomized, placebo-controlled study. J Psychiatr Res 2013;47(5):670-7
   PubMed Web of Science ®Google Scholar
• Ogasa M, Kimura T, Nakamura M, Guarino J. Lurasidone in the treatment of schizophrenia: a 6-week, placebo-controlled study. Psychopharmacology (Berl) 2013;225(3):519-30
   PubMed Web of Science ®Google Scholar
• Loebel A, Cucchiaro J, Sarma K, et al. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: A randomized, double-blind, placebo- and active- controlled trial. Schizophr Res 2013;145(1-3):101-9
   PubMed Web of Science ®Google Scholar
• Potkin SG, Ogasa M, Cucchiaro J, Loebel A. Double-blind comparison of the safety and efficacy of lurasidone and ziprasidone in clinically stable outpatients with schizophrenia and schizoaffective disorder. Schizophr Res 2011;132(2-3):101-37
   PubMed Web of Science ®Google Scholar
• Harvey PD, Ogasa M, Cucchiaro J, et al. Performance an interview-based assessment of cognitive change in a randomized, double-blind comparison of lurasidone versus ziprasidone. Schizophr Res 2011;127(1-3):188-94
   PubMed Web of Science ®Google Scholar
• McEvoy JP, Citrome L, Hernandez D, et al. Effectiveness of lurasidone in patients with schizophrenia and schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study. J Clin Psychiatry 2013;74(2):170-9
   PubMed Web of Science ®Google Scholar
• Barch DM, Bustillo J, Gaebel W, et al. Logic and justification for dimensional assessment of symptoms and related phenomena in psychosis: Relevance to DSM-5. Schizophr Res 2013;150(1):15-20
   PubMed Web of Science ®Google Scholar
• Loebel A, Cucchiaro J, Silva R, et al. Efficacy of lurasidone across five symptom dimensions of schizophrenia: Pooled analysis of short-term, placebo-controlled studies. Eur Psychiatry 2015;30(1):26-31
   PubMed Web of Science ®Google Scholar
• Nasrallah HA, Cucchiaro JB, Mao Y, et al. Lurasidone in the treatment of depressive symptoms in schizophrenia: analysis of 4 pooled, 6-week, placebo-controlled studies. CNS Spectr 2014;23:1-8
   Google Scholar
• Tandon R, Goldman RS, Goodson J, Greden JF. Mutability and relationship between positive and negative symptoms during neuroleptic treatment in schizophrenia. Biol Psychiatry 1990;27(12):1323-6
   PubMed Web of Science ®Google Scholar
• Tapp A, Kilzieh N, Wood AE, et al. Depression in patients with schizophrenia during an acute psychotic episode. Compr Psychiatry 2001;42(4):314-18
   PubMed Web of Science ®Google Scholar
• Goldman R, Tandon R, Liberzon I, Greden JF. Measurement of depressive and negative symptoms in schizophrenia. Psychopathology 1992;25(1):49-56
   PubMed Web of Science ®Google Scholar
• Marder SR, Davis JM, Chouinard G. The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. J Clin Psychiatry 1997;58(12):538-46
   PubMed Web of Science ®Google Scholar
• Tandon R, Goldman RS, DeQuardo JR, et al. Positive and negative symptoms covary during clozapine treatment in schizophrenia. J Psychiatr Res 1993;27:341-7
   Web of Science ®Google Scholar
• Harvey PD, Siu CO, Hsu J, et al. Effect of lurasidone on neurocognitive performance in patients with schizophrenia: A short-term placebo- and active- controlled study followed by a 6-month double-blind extension. European Neuropsychopharmacol 2013;23(11):1373-82
   PubMed Web of Science ®Google Scholar
• Keefe RSE, Bilder RM, Davis SM, et al. Neurocognitive effects of antipsychotic medications in patients with chronic schizophrenia in the CATIE trial. Arch Gen Psychiatry 2007;64(6):633-47
   PubMed Web of Science ®Google Scholar
• Himmeloch S, Taylor SF, Goldman RS, et al. Frontal lobe tasks, antipsychotic medication, and schizophrenia syndromes. Biol Psychiatry 1996;39(3):227-9
   PubMed Web of Science ®Google Scholar
• Citrome L, Cucchiaro J, Sarma K, et al. Long-term safety and tolerability of lurasidone in schizophrenia: a 12-month, double-blind, active-controlled study. Int Clin Psychopharmacol 2012;27(3):165-76
   PubMed Web of Science ®Google Scholar
• Loebel A, Cucchiaro J, Xu J, et al. Effectiveness of lurasidone v quetiapine XR for relapse prevention in schizophrenia: a 12-month, double-blind, noninferiority study. Schizophr Res 2013;147(1):95-102
   PubMed Web of Science ®Google Scholar
• Citrome L, Weiden P, McEvoy JP, et al. Effectiveness of lurasidone in schizophrenia or schizoaffective patients switched from other antipsychotics: a 6-month, open-label, extension study. CNS Spectr 2014;19(4):330-9
   PubMed Web of Science ®Google Scholar
• Stahl SM, Cucchiaro J, Simonelli D, et al. Effectiveness of lurasidone for patients with schizophrenia following 6-weeks of acute treatment with lurasidone, olanzapine, or placebo: a 6-month, open-label, extension study. J Clin Psychiatry 2013;74(5):507-15
   PubMed Web of Science ®Google Scholar
• Tandon R, Loebel A, Phillips D, et al. A double-blind, placebo-controlled, randomized, withdrawal study of lurasidone for the maintenance of efficacy and prevention of relapse in patients with schizophrenia. Schizophr Res 2014;153:S372
   Web of Science ®Google Scholar
• Sanford M. Lurasidone in the treatment of schizophrenia. CNS Drugs 2013;27(1):67-80
   PubMed Web of Science ®Google Scholar
• Taylor SF, Tandon R, Shipley JE, Eiser A. Effect of neuroleptic treatment on polysomnographic measures in schizophrenia. Biol Psychiatry 1991;30(9):904-12
   PubMed Web of Science ®Google Scholar
• Maixner S, Tandon R, Eiser A, et al. Effect of antipsychotic treatment on polysomnographic measures in schizophrenia. Am J Psychiatry 1998;155(11):1600-4
   PubMed Web of Science ®Google Scholar
• Peuskens J, Pani L, Detraux J, DeHert M. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs 2014;28(5):421-53
   PubMed Web of Science ®Google Scholar
• Tandon R, Halbreich U. The second-generation “atypical” antipsychotics: similar improved efficacy but different neuroendocrine side-effects. Psychoneuroendocrinol 2003;28:1-7
   PubMed Web of Science ®Google Scholar
• Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013;382(9896):951-62
   PubMed Web of Science ®Google Scholar
• Tandon R, Targum SD, Nasrallah HA, Ross R. Strategies for maximizing clinical effectiveness in the treatment of schizophrenia. Psychiatr Services 2006;12(6):348-63
   Google Scholar
• Tandon R, Carpenter WT. Psychotic disorders in DSM-5: One-year pre-publication. Schizophr Bull 2012;39:369-70
   Google Scholar
• Heckers S, Barch D, Bustillo J, et al. Structure of the psychotic disorders classification in DSM-5. Schizophr Res 2013;150(1):11-14
   PubMed Web of Science ®Google Scholar
• Carpenter WT, Tandon R. Psychotic disorders in DSM-5. Asian J Psychiatry 2014;6(3):266-8
   Google Scholar
• Tsuang MT, van Os J, Tadon R, et al. Attenuated psychosis in DSM-5. Schizophr Res 2013;150(1):31-35
   PubMed Web of Science ®Google Scholar